Our findings demonstrate that the EP4–YAP signaling axis is a critical pro-metastatic pathway in pancreatic cancer and that pharmacological blockade of EP4 may deliver a therapeutic benefit for patients with metastatic pancreatic cancer. Here, YAP1 is linked to familial pancreatic carcinoma.